Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Adv Therapy

Search In Journal Title:

Abbravation: Advances in Therapy

Search In Journal Abbravation:

Publisher

Springer Healthcare Communications

Search In Publisher:

DOI

10.1002/qua.560090114

Search In DOI:

ISSN

1865-8652

Search In ISSN:
Search In Title Of Papers:

Are Dosing Adjustments Required for Colchicine in

Authors: Suman Wason Robert D Faulkner Matthew W Davis
Publish Date: 2012/06/29
Volume: 29, Issue: 6, Pages: 551-561
PDF Link

Abstract

The objective of this study was to compare the relative bioavailability of the US Food and Drug Administrationapproved formulation of colchicine after a single 06 mg dose in young 18–30 years of age and elderly ≥60 years of age healthy subjects to determine whether dosing adjustments are required in elderly patientsA singledose singledrug parallelgroup study was performed in 20 young subjects with normal renal function defined as creatinine clearance CrCl ≥80 mL/min and 18 elderly subjects with normal or mild renal impairment CrCl ≥50 mL/min in otherwise good health Blood samples were collected for up to 72 hours postdose and analyzed for colchicine using a validated liquid chromatography/tandem mass spectrometry method Noncompartmental pharmacokinetic parameters were compared using analysis of variance methodsThere were no statistically significant P 005 differences in mean colchicine pharmacokinetic parameters between young and elderly subjects including peak plasma concentration C max 253 vs 256 ng/mL time to C max 125 vs 125 hours area under the plasma concentrationtime curve to infinity 2229 vs 2501 ng/h/mL elimination halflife 254 vs 301 hours oral clearance 040 vs 035 L/h/kg and apparent volume of distribution 143 vs 148 L/kg respectivelyThe lack of any significant differences in colchicine pharmacokinetic parameters between young and elderly healthy subjects with some of the latter including mild renal impairment suggests that dose modification of colchicine may not be necessary in healthy elderly patients However when evaluating the use of colchicine dosing in an elderly patient the confounding effect on overall exposure and safety from comorbid conditions the use of concomitant medications and the administration of multiple doses should be consideredThis article is published under an open access license Please check the Copyright Information section for details of this license and what reuse is permitted If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and reuse information please contact the Rights and Permissions team


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Azacytidine for the treatment of myelodysplastic syndromes in the elderly
  2. Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma
  3. Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma
  4. When People with Opioid-Induced Constipation Speak: A Patient Survey
  5. Impacts of Patient Characteristics on the Effectiveness of Landiolol in AF/AFL Patients Complicated with LV Dysfunction: Subgroup Analysis of the J-Land Study
  6. Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
  7. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary
  8. A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components
  9. Individualized Fludarabine-Based Regimen in Elderly Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  10. Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy
  11. Coma caused by isoniazid poisoning in a patient treated with pyridoxine and hemodialysis
  12. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment
  13. An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer
  14. Slovak Trial on Cardiovascular Risk Reduction Following National Guidelines with CaDUET® (The STRONG DUET Study)
  15. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy
  16. Corneal staining reductions observed after treatment with Systane® Lubricant Eye Drops
  17. Cost-Effectiveness of High Dose Hemodialysis in Comparison to Conventional In-Center Hemodialysis in the Netherlands
  18. Advances in Clinical Cardiology
  19. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial
  20. Dose-Finding Study of Landiolol Hydrochloride: A Short-Acting β 1 -Blocker for Controlling Heart Rate During Coronary Computed-Tomography Angiography in Japan
  21. Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals
  22. Glial fibrillary acidic protein (GFAP) and CD34 expression in the human optic nerve and brain in methanol toxicity
  23. Urapidil, a dual-acting antihypertensive agent: Current usage considerations

Search Result: